Japan approves Pirespa for IPF

Japan's Ministry of Health, Labor and Welfare (MHLW) approved an NDA from Shionogi (Osaka, Japan) for Pirespa pirfenidone to treat idiopathic pulmonary fibrosis (IPF). Shionogi has rights to the oral p38 mitogen-activated protein (MAP) kinase inhibitor in Japan, South Korea and Taiwan from Marnac (Dallas, Texas) and KDL (Basel, Switzerland). ...